These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The anaesthetised methoxamine-sensitised rabbit model of torsades de pointes. Carlsson L. Pharmacol Ther; 2008 Aug; 119(2):160-7. PubMed ID: 18558435 [Abstract] [Full Text] [Related]
4. Preclinical Torsades-de-Pointes screens: advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk. Gintant GA. Pharmacol Ther; 2008 Aug; 119(2):199-209. PubMed ID: 18621077 [Abstract] [Full Text] [Related]
5. Torsades de pointes liability inter-model comparisons: the experience of the QT PRODACT initiative. Hashimoto K. Pharmacol Ther; 2008 Aug; 119(2):195-8. PubMed ID: 18486227 [Abstract] [Full Text] [Related]
7. Juvenile animal toxicity study designs to support pediatric drug development. Cappon GD, Bailey GP, Buschmann J, Feuston MH, Fisher JE, Hew KW, Hoberman AM, Ooshima Y, Stump DG, Hurtt ME. Birth Defects Res B Dev Reprod Toxicol; 2009 Dec; 86(6):463-9. PubMed ID: 20025047 [Abstract] [Full Text] [Related]
8. Early clinical development: evaluation of drug-induced torsades de pointes risk. Vik T, Pollard C, Sager P. Pharmacol Ther; 2008 Aug; 119(2):210-4. PubMed ID: 18601950 [Abstract] [Full Text] [Related]
9. Evaluations of organ system development in juvenile toxicology testing. Robinson K. Reprod Toxicol; 2008 Sep; 26(1):51-3. PubMed ID: 18595655 [Abstract] [Full Text] [Related]
10. Perception of validity of clinical and preclinical methods for assessment of torsades de pointes liability. Pugsley MK, Hancox JC, Curtis MJ. Pharmacol Ther; 2008 Aug; 119(2):115-7. PubMed ID: 18590766 [Abstract] [Full Text] [Related]
11. Safety evaluation to support First-In-Man investigations I: kinetic and safety pharmacology studies. Baldrick P. Regul Toxicol Pharmacol; 2008 Jul; 51(2):230-6. PubMed ID: 18501489 [Abstract] [Full Text] [Related]
14. Use of the rabbit with a failing heart to test for torsadogenicity. Hamlin RL, Kijtawornrat A. Pharmacol Ther; 2008 Aug; 119(2):179-85. PubMed ID: 18691764 [Abstract] [Full Text] [Related]
15. Real life juvenile toxicity case studies: the good, the bad and the ugly. De Schaepdrijver L, Rouan MC, Raoof A, Bailey GP, De Zwart L, Monbaliu J, Coogan TP, Lammens L, Coussement W. Reprod Toxicol; 2008 Sep; 26(1):54-5. PubMed ID: 18514481 [Abstract] [Full Text] [Related]
17. [Methodological characteristics of the preclinical study of the safety of drug preparations for children]. Mal'tseva LF, Muratova GP, Motovilova VG, Sirinova NA. Farmakol Toksikol; 1988 Sep; 51(4):96-100. PubMed ID: 3191987 [Abstract] [Full Text] [Related]
18. What have we learned from pre-clinical juvenile toxicity studies? Bailey GP, Mariën D. Reprod Toxicol; 2009 Sep; 28(2):226-9. PubMed ID: 19446432 [Abstract] [Full Text] [Related]
19. Supplemental studies for cardiovascular risk assessment in safety pharmacology: a critical overview. Picard S, Goineau S, Guillaume P, Henry J, Hanouz JL, Rouet R. Cardiovasc Toxicol; 2011 Dec; 11(4):285-307. PubMed ID: 21805209 [Abstract] [Full Text] [Related]
20. Optimising the design of preliminary toxicity studies for pharmaceutical safety testing in the dog. Smith D, Combes R, Depelchin O, Jacobsen SD, Hack R, Luft J, Lammens L, von Landenberg F, Phillips B, Pfister R, Rabemampianina Y, Sparrow S, Stark C, Stephan-Gueldner M. Regul Toxicol Pharmacol; 2005 Mar; 41(2):95-101. PubMed ID: 15698532 [Abstract] [Full Text] [Related] Page: [Next] [New Search]